Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Guangdong Kanghua Healthcare Group Co., Ltd. (3689.HK)
Dongguan, CN
Guangdong Kanghua Healthcare Group Co., Ltd. primarily operates private hospitals in the People's Republic of China. The company operates through four segments: Hospital Services, Rehabilitation and Other Healthcare Services, Haemodialysis Services, and Elderly Healthcare Services. It provides inpatient and outpatient healthcare, and physical examination services. The company also offers reproductive medicine; plastic and aesthetic surgery; and laser treatment services. In addition, it provides rehabilitation services to patients with physical or mental disabilities; treatments that replicate kidney's function to remove wastes in blood for patients with kidney conditions; and other healthcare-related services, including elderly care and training service for the disabled. Further, the company offers elderly healthcare services, including assisted living, adult daycare, long-term care, residential care, and hospice care to the aged patients. Additionally, it operates Kanghua Hospital, Renkang Hospital, and Kangxin Hospital names; and offers management, hospital management, and property holding services. Guangdong Kanghua Healthcare Group Co., Ltd. was formerly known as Guangdong Kanghua Healthcare Co., Ltd. and changed its name to Guangdong Kanghua Healthcare Group Co., Ltd. in August 2024. The company was incorporated in 2002 and is based in Dongguan, China. Guangdong Kanghua Healthcare Group Co., Ltd. operates as a subsidiary of Dongguan Kanghua Investment Group Co., Ltd.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.55% | -1.04% | -7.32% | -5.00% | +5.56% | +9.83% | -2.56% | +21.79% | -34.48% | -82.08% | -82.08% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Care Facilities: +10.2%-4.1% Q4'25: -2.8% (vs Q4'23)
-
EPS growth Medical - Care Facilities: +19.2%+530.4% ★ Q4'25: -19.0% (vs Q4'23)
-
FCF margin FCF growth · Medical - Care Facilities: +32.0%+6.5% Q4'25: +8.6% (vs Q4'23)
-
EBIT margin Medical - Care Facilities: +11.3%+5.8% Q4'25: +7.4% (vs Q4'23)
-
ROIC Medical - Care Facilities: +6.8%+6.8% Q4'25: +19.0% (vs Q4'23)
-
Share dilution Medical - Care Facilities: +0.0%+0.0% Q4'25: +0.0% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Care Facilities: 0.99×1.31× ★ Q4'25: 0.56× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.24B
est: 1.27B (-2.3%)
|
1.39B
est: 1.44B (-3.5%)
|
1.64B
est: 1.55B (+5.6%)
|
1.96B
est: 1.90B (+2.9%)
|
1.75B
est: 1.99B (-12.1%)
|
1.95B
est: 2.14B (-8.6%)
|
1.85B
est: 2.27B (-18.7%)
|
2.04B
est: 2.82B (-27.7%)
|
2.06B
est: 2.62B (-21.5%)
|
| EBITDA |
229.13M
est: 157.02M (+45.9%)
|
253.48M
est: 255.21M (-0.7%)
|
269.74M
est: 302.19M (-10.7%)
|
257.33M
est: 234.97M (+9.5%)
|
138.79M
est: 368.42M (-62.3%)
|
298.46M
est: 264.36M (+12.9%)
|
233.79M
est: 280.52M (-16.7%)
|
305.92M
est: 452.37M (-32.4%)
|
224.86M
est: 350.07M (-35.8%)
|
| EBIT |
205.92M
est: 59.91M (+243.7%)
|
218.08M
est: 230.41M (-5.4%)
|
222.69M
est: 250.45M (-11.1%)
|
134.73M
est: 89.65M (+50.3%)
|
-4.09M
est: 305.34M (-101.3%)
|
149.02M
est: 327.42M (-54.5%)
|
84.35M
est: 107.03M (-21.2%)
|
162.84M
est: 374.92M (-56.6%)
|
75.00M
est: 155.74M (-51.8%)
|
| Net Income |
141.26M
est: 160.87M (-12.2%)
|
156.59M
est: 158.06M (-0.9%)
|
167.94M
est: 179.84M (-6.6%)
|
48.69M
est: 200.97M (-75.8%)
|
-25.37M
est: 219.25M (-111.6%)
|
94.31M
est: 111.19M (-15.2%)
|
59.70M
est: 167.19M (-64.3%)
|
121.06M
est: 269.21M (-55.0%)
|
15.34M
est: 338.85M (-95.5%)
|
| SGA |
109.04M
est: 158.25M (-31.1%)
|
126.99M
est: 122.26M (+3.9%)
|
185.18M
est: 149.88M (+23.5%)
|
232.28M
est: 236.82M (-1.9%)
|
227.77M
est: 182.73M (+24.7%)
|
225.22M
est: 266.43M (-15.5%)
|
228.32M
est: 282.72M (-19.2%)
|
242.39M
est: 224.37M (+8.0%)
|
277.10M
est: 324.22M (-14.5%)
|
| EPS |
0.54
est: 0.48 (+12.2%)
|
0.47
est: 0.51 (-8.6%)
|
0.50
est: 0.44 (+13.9%)
|
0.15
est: 0.60 (-75.0%)
|
-0.08
est: 0.24 (-132.3%)
|
0.28
est: 0.33 (-15.8%)
|
0.18
est: 0.50 (-64.0%)
|
0.36
est: 1.02 (-64.8%)
|
0.05
est: 1.01 (-95.4%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-22 | A | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-21 | A | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-20 | A | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-19 | A | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-18 | A | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-15 | A | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-14 | A | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-13 | A | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-06 | A | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Wangzhi Chen | Chief Executive Officer & Executive Director | 2M | male |
| Wai Hung Wong | Executive Vice Chairman | 1M | male |
| Aiqin Wang | Executive Director | 346.4K | female |
| Junyang Wang | Executive Chairman of the Board | 207.8K | male |
| Li Chen | Financial Controller | — | female |
| Wai Hang Wong | Chief Financial Officer, Joint Company Secretary & Secretary to the Board | — | male |
| Hing Ling Chau FCIS | Joint Company Secretary | — | female |
| Baizhi Wang | Vice General Manager of Operation | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 3689.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
